Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial.

Plain-language guide to PMID 26690008 (2016): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 141 patients.

Key Facts

PMID: 26690008
Journal: Fertility and sterility
Year: 2016
Study type: Randomized Controlled Trial
Authors: Bassiouny YA et al. (4 authors)
DOI: 10.1016/j.fertnstert.2015.11.026
Registered trial: NCT02195947

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Who Took Part

The abstract describes 141 patients taking part.

PubMed tags the participants as women only.

A total of 141 patients (GH, n = 68; gonadotropins only, n = 73) were enrolled.

Twenty-five patients had their cycles cancelled.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the patients and staff both knew the treatment.

The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.

Parallel randomized, controlled, open-label trial.

Analysis was performed per cycle start as well as per ET.

Patients received the antagonist protocol with or without GH supplementation.

What Was Measured

The subject headings attached to it are Abortion, Spontaneous, Egypt, Embryo Implantation, Embryo Transfer, Fertility, Fertility Agents, Female and Fertilization in Vitro.

Author keywords: Antagonist protocol, IVF/ICSI, poor ovarian response and poor responders.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 141 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (Fertility and sterility), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.